Skip to main content
    Q

    QuidelOrtho Corp (QDEL)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $10.21
    -0.53 (-4.93%)

    Market Cap: $736.90M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    QuidelOrtho Corp (QDEL) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    QuidelOrtho (QDEL) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, QuidelOrtho reported EPS of $0.31, above the $0.18 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    74%(29/39)
    Avg Surprise
    +26.50%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 9, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.26
    Range$0.25 - $0.27
    5 analysts
    Revenue Consensus
    $662.93M
    Range$627.69M - $690.16M
    5 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.06
    Range-$0.06 - -$0.05
    2 analysts
    EPS Estimate DriftChange to current
    90d ago$0.02-375.0%
    60d ago$0.01-650.0%
    30d ago$0.01-650.0%
    7d ago$0.00n/a
    Current-$0.06
    Revenue Consensus
    $600.60M
    Range$592.50M - $608.70M
    2 analysts

    Next Report

    QDEL has an expected report date of Feb 9, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 43.5% below the $0.46 reported for the quarter ended Dec 31, 2025.

    QDEL Earnings Call

    The latest QDEL earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, QDEL beat 29, missed 9 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $618.90M, down 11.6% from $699.90M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.31$0.18$0.18 - $0.18+72.22%Beat-61.3%10 up, 1 downNov 3, 2026$618.90M
    Jun 30, 2026$0.13-$0.04-$0.05 - -$0.04+425.00%Beat+8.3%20 up, 1 downAug 6, 2026$630.90M
    Mar 31, 2026-$0.04$0.36$0.35 - $0.56-111.11%Miss-105.4%40 up, 1 downMay 5, 2026$619.80M
    Dec 31, 2025$0.46$0.42$0.39 - $0.45+9.52%Beat-27.0%60 up, 1 downFeb 11, 2026$723.60M
    Sep 30, 2025$0.80$0.51$0.37 - $0.57+56.86%Beat-5.9%61 up, 3 downNov 5, 2025$699.90M
    Jun 30, 2025$0.12$0.01-$0.09 - $0.07N/AN/AN/A60 up, 0 downAug 5, 2025$613.90M
    Mar 31, 2025$0.74$0.59$0.46 - $0.67+25.42%Beat+68.2%70 up, 2 downMay 7, 2025$692.80M
    Dec 31, 2024$0.63$0.58$0.48 - $0.68+8.62%Beat-46.2%81 up, 0 downFeb 12, 2025$707.80M
    Sep 30, 2024$0.85$0.32$0.22 - $0.43+165.63%Beat-5.6%80 up, 0 downNov 7, 2024$727.10M
    Jun 30, 2024-$0.07-$0.24-$0.35 - -$0.07+70.83%Beat-126.9%70 up, 0 downJul 31, 2024$637.00M
    Mar 31, 2024$0.44$0.40$0.25 - $0.56+10.00%Beat-75.6%70 up, 0 downMay 8, 2024$711.00M
    Dec 31, 2023$1.17$2.06$1.87 - $2.23-43.20%Miss-33.5%80 up, 0 downFeb 13, 2024$742.60M
    Sep 30, 2023$0.90$0.56$0.40 - $1.10+60.71%Beat-51.4%83 up, 0 downNov 1, 2023$744.00M
    Jun 30, 2023$0.26$0.26$0.02 - $0.420.00%In line-88.9%81 up, 0 downAug 8, 2023$665.10M
    Mar 31, 2023$1.80$1.43$1.31 - $1.95+25.87%Beat-84.6%83 up, 0 downMay 3, 2023$846.10M
    Dec 31, 2022$1.76$1.42$1.31 - $1.61+23.94%Beat-75.9%80 up, 0 downFeb 15, 2023$866.50M
    Sep 30, 2022$1.85$0.69$0.49 - $1.17+168.12%Beat-65.5%73 up, 0 downNov 2, 2022$783.80M
    Jun 30, 2022$2.34$2.68N/A-12.69%Miss+212.0%N/A1 up, 0 downAug 4, 2022$613.40M
    Mar 31, 2022$11.66$9.43$7.93 - $11.75+23.65%Beat+166.2%52 up, 0 downMay 4, 2022$1.00B
    Dec 31, 2021$7.29$5.61$4.31 - $6.76+29.95%Beat-34.1%50 up, 0 downFeb 17, 2022$636.87M
    Sep 30, 2021$5.36$2.30$0.82 - $5.39+133.04%Beat-7.3%5N/ANov 4, 2021$509.80M
    Jun 30, 2021$0.75$1.19$0.92 - $1.60-36.97%Miss-59.7%6N/AAug 5, 2021$176.60M
    Mar 31, 2021$4.38$4.68$3.93 - $5.07-6.41%Miss+259.0%6N/AMay 6, 2021$375.34M
    Dec 31, 2020$11.07$10.10$9.68 - $10.47+9.60%Beat+1007.0%6N/AFeb 18, 2021$809.20M
    Sep 30, 2020$5.78$4.70$4.09 - $5.20+22.98%Beat+725.7%6N/AOct 29, 2020$476.06M
    Jun 30, 2020$1.86$1.09$0.84 - $1.81+70.64%Beat+416.7%6N/AJul 30, 2020$201.75M
    Mar 31, 2020$1.22$0.95$0.86 - $1.16+28.42%Beat+34.1%6N/AMay 6, 2020$174.65M
    Dec 31, 2019$1.00$0.82$0.74 - $0.92+21.95%Beat+25.0%6N/AFeb 12, 2020$152.18M
    Sep 30, 2019$0.70$0.64$0.59 - $0.70+9.38%Beat+18.6%6N/AOct 30, 2019$126.49M
    Jun 30, 2019$0.36$0.37N/A-2.70%Miss0.0%5N/AAug 8, 2019$108.25M
    Mar 31, 2019$0.91$1.05$0.99 - $1.07-13.33%Miss-29.5%5N/AMay 8, 2019$147.97M
    Dec 31, 2018$0.80$0.63$0.43 - $0.69+26.98%Beat+247.8%6N/AFeb 13, 2019$132.59M
    Sep 30, 2018$0.59$0.49$0.39 - $0.59+20.41%Beat+227.8%7N/ANov 6, 2018$117.40M
    Jun 30, 2018$0.36$0.27$0.15 - $0.30+33.33%BeatN/A6N/AAug 7, 2018$103.16M
    Mar 31, 2018$1.29$0.98$0.94 - $1.17+31.63%Beat+186.7%7N/AMay 8, 2018$169.14M
    Dec 31, 2017$0.23$0.20-$0.14 - $0.40+15.00%BeatN/A4N/AFeb 21, 2018$114.89M
    Sep 30, 2017$0.18$0.13N/A+38.46%Beat+80.0%5N/ANov 1, 2017$50.89M
    Jun 30, 2017-$0.12-$0.09N/A-33.33%MissN/A6N/AJul 26, 2017$38.27M
    Mar 31, 2017$0.45$0.29N/A+55.17%Beat+2150.0%N/AN/AApr 24, 2017$73.69M
    Dec 31, 2016-$0.06$0.02N/A-400.00%MissN/AN/AN/AFeb 8, 2017$52.81M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $2.12, up 14.6% from the year before. It was -$0.05 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$2.12+14.6%
    Dec 31, 2024$1.85-55.2%
    Dec 31, 2023$4.13-76.5%
    Dec 31, 2022$17.61-1.0%
    Dec 31, 2021$17.78-10.8%
    Dec 31, 2020$19.93+571.0%
    Dec 31, 2019$2.97-2.3%
    Dec 31, 2018$3.04+310.8%
    Dec 31, 2017$0.74N/A
    Dec 31, 2016-$0.05N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,4828
    2026Q2Jun 30, 20263,6206
    2026Q1Mar 31, 20263,9458
    2025Q4Dec 31, 20257,74613
    2025Q3Sep 30, 20253,5927
    2025Q2Jun 30, 20256,20712
    2025Q1Mar 31, 20255,37312
    2024Q4Dec 31, 20246,57113

    2026Q3 Earnings Call

    Opening remarks

    Sanjeev Sharma Vice President of Investor Relations Good afternoon, everyone, and thank you for joining us on our earnings call. With us today, we have Brian Blaser, our President and Chief Executive Officer; and Micah Young, our Chief Financial Officer. This conference call is being simultaneously webcast on the IR section of our website. To assist in the presentation, we also posted supplemental information on the Investor Relations page that will be referenced throughout this call. Please note that this conference call and supplemental information contain forward-looking statements, including the company's expectations, plans, financial guidance and various strategic initiatives. We assume no obligation to update any forward-looking statements, except as required by law. These statements are made as of today and are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in these statements. Please refer to our SEC filings for a description of potential risks. In addition, today's call includes discussion of certain non-GAAP financial measures. Tables reconciling these non-GAAP measures to their most directly comparable GAAP measures are available in our earnings release and supplemental information on the Investor Relations page of our website. Lastly, unless stated otherwise, all year-over-year revenue growth rates given on today's call are on a constant currency basis. With that, I would like to turn the call over to our President and CEO, Brian Blaser.

    Brian Blaser President and Chief Executive Officer Thanks, Sanjeev, and good afternoon, everyone. I'd like to begin with 3 important takeaways from the quarter. First, the underlying performance of our business remains resilient. Labs and immunohematology, which represents 70% to 75% of our revenue, excluding China, delivered low to mid-single-digit organic growth. Second, our reported results continue to reflect 2 significant near-term headwinds, the impact of China's now finalized nationwide IVD pricing guidelines and the softer respiratory testing environment in point of care. Third, we are acting decisively and launching a new cost transformation and enterprise restructuring program designed to improve profitability and cash generation while evolving our operating model around the distinct needs of our customers and markets. These actions are intended to strengthen execution today and position QuidelOrtho for sustainable, profitable growth over the long term. Turning to our third quarter results. Total reported revenue was $619 million, down 12% from last year. Revenue increased 3%, excluding China, respiratory and the prior year contribution from the U.S. Donor Screening business, which we are winding down. Labs revenue outside China grew 4%, supported by the strength and durability of our customer relationships and large global installed base. Immunohematology revenue outside China increased 3%, reflecting steady demand across key markets and our strong position in the segment. Together, these results reinforce an important point. The underlying fundamentals of our business remain healthy.

    Frequently Asked Questions About QDEL

    When is QuidelOrtho's next earnings date?

    QuidelOrtho's next earnings report is expected for Feb 9, 2027.

    Did QDEL beat earnings estimates last quarter?

    Yes. QuidelOrtho reported EPS of $0.31 for the quarter ended Sep 30, 2026, above the $0.18 estimate, a 72.22% surprise.

    What EPS do analysts expect from QDEL next quarter?

    The consensus EPS estimate for QuidelOrtho for the quarter ending Dec 31, 2026 is $0.26 from 5 analysts, with estimates from $0.25 to $0.27.

    How often does QDEL beat earnings estimates?

    QuidelOrtho beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +81.52%.